Chinese expert consensus on the evaluation of neurological immune-related adverse reactions in malignant tumors treated with immune checkpoint inhibitors by MRI
In recent years,cancer immunotherapy,especially immune checkpoint inhibitors(ICIs),has become an important breakthrough in tumor treatment,significantly improving patient prognosis.However,the occurrence of immune-related adverse events(irAEs),particularly those affecting the nervous system,is one of the main limitations of cancer immunotherapy,with an associated mortality rate exceeding 5%.MRI plays a key role in detecting and assessing neurological irAEs.However,there is currently a lack of standardized consensus in China regarding MRI examination and diagnosis of neurological irAEs caused by ICIs.To address this,the Molecular Imaging Group,Magnetic Resonance Group,and Neurology Group of the Radiology Branch of the Chinese Medical Association,along with the Editorial Board of Chinese Journal of Magnetic Resonance Imaging,are committed to formulating a consensus on MRI examination and diagnostic reporting for neurological irAEs caused by ICIs.After reviewing the literature,expert experience,and internal member discussions,this committee has reached a consensus aimed at providing more accurate empirical support for imaging and clinical physicians and promoting the application of MRI technology in the diagnosis of neurological irAEs.
magnetic resonance imagingimmune checkpoint inhibitorsneurological immune-related adverse reactionsclinical applicationexpert consensus
万方数据
维普
